

Clinical Biomarkers

Analyte Type	Disease	Analytes	Regulatory Compliance	Limit of Detection	Method	Sample Type	Product Name
Somatic gene mutations	Oncology	12 gene panel	CLIA	1-5%	NGS	Tissue / FFPE	OncoGxSelect™
		64 gene panel	CLIA	1-5%	NGS	Tissue / FFPE	OncoGxOne™
		10 gene panel (BRAF, KRAS, EGFR, ERBB2, PIK3CA, AKT1, ALK, ROS1, RET, MET)	CLIA soon	0.10%	NGS	Blood	LiquidGx™ Lung
		EGFR (T790M, L858R, Exon19 del)	CLIA	0.01 – 0.05%	qPCR	Blood	LiquidGx™ EGFR
		BRAF (V600E)	CLIA	0.01%	qPCR	Blood	LiquidGx™ BRAF
		KRAS (G12)	CLIA	0.01%	qPCR	Blood	LiquidGx™ KRAS
		Additional genes (ERBB2, PIK3CA, NRAS, ALK, ROS1, RET, MET, etc.)	CLIA soon	0.01%	qPCR	Blood	LiquidGx™ X
Germline gene variations	Cardiovascular	213 gene panel	CLIA	n/a	NGS	Blood, saliva	CardioGxOne™
		84 gene panel	CLIA	n/a	NGS	Blood, saliva	AtheroGxOne™
	Pharmacogenomics	50 gene panel	CLIA	n/a	NGS	Blood, saliva, buccal swab	PGxOne™ Plus
Protein markers	Oncology	CYFRA21-1, ProGRP, NSE, A1AT, CRP, SAA1, Follistatin, SMRP, HE4, CEA, etc.	Under active development	0.1-1nM	Aptamer	Blood	UltraD
Methylation markers	Oncology	SEPT9, MGMT, BCAT1, IKZF1, SDC2	Under active development	n/a	qPCR	Blood	

We provide development, regulatory CLIA/CAP approval and LDT testing for DNA, RNA, methylation and protein biomarkers of interest